<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04039711</url>
  </required_header>
  <id_info>
    <org_study_id>RCB 2014-A01250-47</org_study_id>
    <nct_id>NCT04039711</nct_id>
  </id_info>
  <brief_title>Evaluation of Vaginal Self-sampling Diagnostic Performances to Identify Genital Infections</brief_title>
  <official_title>Evaluation of Vaginal Self-sampling Diagnostic Performances to Identify Genital Infections : A Large, Cross-sectional, Non-inferiority Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Européen Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Européen Marseille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Screening for genital infection (GI), sexually transmitted infection (STI) and asymptomatic
      carriage of group B streptococcus (GBS) in pregnant women is a common reason for medical
      appointments. Conventional testing is performed by using vaginal and/or cervical classic
      sampling (VCS). Vaginal self-sampling (VSS) has progressively emerged as an alternative to
      VCS for STI agent screening. The use of vaginal self-sampling (VSS) could facilitate
      follow-ups and potentially help in the prevention of gynaecological disorders.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2015</start_date>
  <completion_date type="Actual">April 6, 2018</completion_date>
  <primary_completion_date type="Actual">April 6, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Participants were screenned for genital infections
performing vaginal and/or cervical classical-sampling (VCS)
performing vaginal self-sampling (VSS)</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bacterial infection detection rates</measure>
    <time_frame>10 days</time_frame>
    <description>Bacterial infection detection rates of VSS compared with VCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Yeast infection detection rates</measure>
    <time_frame>10 days</time_frame>
    <description>Yeast infection detection rates of VSS compared with VCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Chlamydia trachomatis detection rates</measure>
    <time_frame>10 days</time_frame>
    <description>Chlamydia trachomatis detection rates of VSS compared with VCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neisseria gonorrhoeae detection rates</measure>
    <time_frame>10 days</time_frame>
    <description>Neisseria gonorrhoeae detection rates of VSS compared with VCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mycoplasma genitalium detection rates</measure>
    <time_frame>10 days</time_frame>
    <description>Mycoplasma genitalium detection rates of VSS compared with VCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trichomonas vaginalis detection rates</measure>
    <time_frame>10 days</time_frame>
    <description>Trichomonas vaginalis detection rates of VSS compared with VCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Human simplex virus detection rates</measure>
    <time_frame>10 days</time_frame>
    <description>Human simplex virus detection rates of VSS compared with VCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Group B streptococcus detection rates</measure>
    <time_frame>10 days</time_frame>
    <description>Group B streptococcus detection rates of VSS compared with VCS</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1028</enrollment>
  <condition>Genital Infection</condition>
  <condition>Asymptomatic Infections</condition>
  <arm_group>
    <arm_group_label>Genital infections</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women with vaginal/cervical sampling indications</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Vaginal self-sampling</intervention_name>
    <description>The objective is to determine the non-inferiority of vaginal self-sampling compared with vaginal/cervical classical sampling, and evaluate the possibility of using it in all clinical situations indicating the prescription of such a procedure to screen for genital infections (GIs), sexually transmitted infections (STIs) and group B streptococcus (GBS) asymptomatic carriage in pregnant women.</description>
    <arm_group_label>Genital infections</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women requiring vaginal or cervical classical sampling to screen for genital
             infections

          -  Women requiring vaginal or cervical classical sampling to screen for sexually
             transmitted infections (STI)

          -  Pregnant women requiring vaginal classical sampling to screeen for Group B
             streptococcus asymptomatic carriage in the eighth month of pregnancy

          -  Informed written consent from the patient

        Exclusion Criteria:

          -  Person subjected to therapeutic limitation decision

          -  Women with intact hymen

          -  Active antibiotic or antifungic treatment

          -  Antiobiotic or antifungic treatment during the 10 days prior to inclusion
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>European Hospital</name>
      <address>
        <city>Marseille</city>
        <state>Bouches-du Rhone</state>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Hobbs MM, van der Pol B, Totten P, Gaydos CA, Wald A, Warren T, Winer RL, Cook RL, Deal CD, Rogers ME, Schachter J, Holmes KK, Martin DH. From the NIH: proceedings of a workshop on the importance of self-obtained vaginal specimens for detection of sexually transmitted infections. Sex Transm Dis. 2008 Jan;35(1):8-13.</citation>
    <PMID>18157061</PMID>
  </results_reference>
  <results_reference>
    <citation>Lunny C, Taylor D, Hoang L, Wong T, Gilbert M, Lester R, Krajden M, Ogilvie G. Self-Collected versus Clinician-Collected Sampling for Chlamydia and Gonorrhea Screening: A Systemic Review and Meta-Analysis. PLoS One. 2015 Jul 13;10(7):e0132776. doi: 10.1371/journal.pone.0132776. eCollection 2015. Review.</citation>
    <PMID>26168051</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 29, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>August 1, 2019</last_update_submitted>
  <last_update_submitted_qc>August 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Européen Marseille</investigator_affiliation>
    <investigator_full_name>Edwin QUARELLO @me.com</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Vaginal self-sampling</keyword>
  <keyword>STI</keyword>
  <keyword>Genital infection</keyword>
  <keyword>Group B streptococcus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Asymptomatic Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

